Inhibition of Aldosterone in Patients With Chronic Renal Disease
Launched by LENE BOESBY · Feb 1, 2007
Trial Information
Current as of June 05, 2025
Completed
Keywords
ClinConnect Summary
Patients with chronic renal disease are likely to progress to end stage renal disease with the need for renal replacement therapy. It is accepted that proteinuria is a surrogate measurement for progression. If proteinuria can be lowered we hope to prolong patients pre-dialysis phase. Our theory is that aldosterone inhibition will lead to this.
For a period of 8 weeks patients will be randomized to either aldosterone receptor inhibition with the drug eplerenone or control without. Blood pressures will be kept at the same level using other drugs.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Proteinuria \> 500 mg/24 hours
- • Hypertension or anti-hypertensive treatment
- Exclusion Criteria:
- • Diabetic nephropathy
- • GFR\< 20 ml/min
- • P-potassium between 3,5 mmol/l and 5,0 mmol/l
About Lene Boesby
Lene Boesby is a dedicated clinical trial sponsor with a strong commitment to advancing medical research and improving patient outcomes. With extensive experience in the design and management of clinical studies, Lene focuses on fostering innovative solutions in therapeutic areas that address unmet medical needs. By collaborating with leading researchers and healthcare professionals, she aims to ensure the integrity and quality of clinical data while adhering to the highest ethical standards. Lene's passion for patient-centric research underscores her mission to contribute meaningfully to the development of safe and effective treatments.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Copenhagen, , Denmark
Herlev, , Denmark
Patients applied
Trial Officials
Svend Strandgaard, DMSc
Study Director
Anne-Lise Kamper, DMSc
Study Director
nonaffiliated
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials